mRNA 重編程技術優勢
誘導性多功能幹細胞 (Induced Pluripotent Stem Cells, iPSCs) 在臨床應用上的關鍵安全性問題 (1) 基因組整合的風險 (2) 細胞內殘留的重編程載體，而 RNA 重編程技術 (RNA reprogramming technology) 透過細胞自然降解外來 RNA 的過程，不但可以避免基因組整合、也最大程度地降低突變風險，並維持 iPSC 的遺傳完整性。
mRNA 在細胞質中被轉譯成重編程因子 (reprogramming factors)，後續殘留的 RNA 會被宿主細胞快速降解，所產生的 iPSC 具有臨床安全性。
研究用 iPSC
- Research Use Only
- 使用 StemRNA 3rd Gen 重編程技術
- 非整合型方法、不殘留重編程載體
- 與自行重編程細胞相比，可以節省大量時間
產品列表
| Cat. No. | Strain ID | Donor Race | Donor Sex | Donor Age | Donor Clinical Status | Tissue Source |
| RCRP004N | RPChiPS8023G1 | Hispanic | Female | 30 | Healthy | Blood (EPCs) |
| RCRP005N | RPChiPS7713G1 | Caucasian | Male | 32 | Healthy | Blood (EPCs) |
| RCRP006N | RPChiPSSK0011 | Asian-Indian | Male | 56 | Healthy | Skin (Fibroblasts) |
| RCRP007N | RPChiPSSK0042 | Asian-Indian | Male | 65 | Healthy | Skin (Fibroblasts) |
| RCRP008N | RPChiPSSK0021 | Asian-Indian | Female | 58 | Healthy | Skin (Fibroblasts) |
| RCRP009N | RPChiPSBL003 | Asian-Indian | Female | 20 | Healthy | Blood (EPCs) |
| RCRP010N | RPChiPSSK0053 | Caucasian | Male | 56 | Healthy | Skin (Fibroblasts) |
| RCRP011N | RPChiPSSK0032 | Asian-Indian | Female | 20 | Healthy | Skin (Fibroblasts) |
| RCRP012N | RPChiPSSK006 | Filipino | Male | 30 | Healthy | Skin (Fibroblasts) |
| RCRP031N | RPChiPSSK014 | Asian | Male | 46 | Healthy | Skin (Fibroblasts) |
| RCRP032N | RPChiPSSK012 | African-American | Male | 22 | Healthy | Skin (Fibroblasts) |
| RCRP036N | RPChiPSSK013 | Caucasian | Male | 24 | Healthy | Skin (Fibroblasts) |
| RCRP037P | RPChiPSSK015 | Caucasian | Male | 58 | Parkinson’s Disease | Skin (Fibroblasts) |
產品規格
點擊產品名稱查閱原廠說明
| StemRNA™ Human iPSC 802-3G RCRP004N RPChiPS8023G1 iPSCs reprogrammed from EPCs derived from blood ethically sourced from a Hispanic female, aged 30. |
| StemRNA™ Human iPSC 771-3G RCRP005N RPChiPS7713G1 iPSCs reprogrammed from EPCs derived from blood ethically sourced from a Caucasian male, aged 32. |
| StemRNA™ Human iPSC SK001.1 RCRP006N RPChiPSSK0011 iPSCs reprogrammed from fibroblasts derived from skin ethically sourced from an Asian-Indian male, aged 56. |
| StemRNA™ Human iPSC SK004.2 RCRP007N RPChiPSSK0042 iPSCs reprogrammed from fibroblasts derived from skin ethically sourced from an Asian-Indian male, aged 65. |
| StemRNA™ Human iPSC SK002.1 RCRP008N RPChiPSSK0021 iPSCs reprogrammed from fibroblasts derived from skin ethically sourced from an Asian-Indian female, aged 58. |
| StemRNA™ Human iPSC BL003 RCRP009N RPChiPSBL003 iPSCs reprogrammed from EPCs derived from blood ethically sourced from an Asian-Indian female, aged 20. |
| StemRNA™ Human iPSC SK005.3 RCRP010N RPChiPSSK0053 iPSCs reprogrammed from fibroblasts derived from skin ethically sourced from an Caucasian male, aged 56. |
| StemRNA™ Human iPSC SK003.2 RCRP011N RPChiPSSK0032 iPSCs reprogrammed from fibroblasts derived from skin ethically sourced from a Asian-Indian female, aged 20. |
| StemRNA™ Human iPSC SK006.4 RCRP012N RPChiPSSK0064 iPSCs reprogrammed from fibroblasts derived from skin ethically sourced from an Filipino male, aged 30. |
| StemRNA™ Human iPSC SK014 RCRP031N RPChiPSSK014 iPSCs reprogrammed from fibroblasts derived from skin ethically sourced from an Asian male, aged 46. |
| StemRNA™ Human iPSC SK012 RCRP032N Ready to use IPS Cells made using the Cutting-Edge StemRNA 3rd Gen Reprogramming Technology. |
| StemRNA™ Human iPSC SK013 RCRP036N Ready to use IPS Cells made using the Cutting-Edge StemRNA 3rd Gen Reprogramming Technology. |
| StemRNA™ Human iPSC SK015 RCRP037P Ready to use PD Patient IPS Cells made using the Cutting-Edge StemRNA 3rd Gen Reprogramming Technology. |
相關產品
世翔國際有限公司